DE3751004D1 - Chimärer Antikörper mit Spezifität für menschliches Tumor-Antigen. - Google Patents

Chimärer Antikörper mit Spezifität für menschliches Tumor-Antigen.

Info

Publication number
DE3751004D1
DE3751004D1 DE3751004T DE3751004T DE3751004D1 DE 3751004 D1 DE3751004 D1 DE 3751004D1 DE 3751004 T DE3751004 T DE 3751004T DE 3751004 T DE3751004 T DE 3751004T DE 3751004 D1 DE3751004 D1 DE 3751004D1
Authority
DE
Germany
Prior art keywords
chimeric antibody
tumor antigen
human tumor
antibody specific
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751004T
Other languages
English (en)
Other versions
DE3751004T2 (de
Inventor
Alvin Y Liu
Randy R Robinson
Karl Erik Hellstrom
Ingegerd Hellstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DE3751004D1 publication Critical patent/DE3751004D1/de
Publication of DE3751004T2 publication Critical patent/DE3751004T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Details Of Garments (AREA)
  • Luminescent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE3751004T 1986-10-27 1987-10-27 Chimärer Antikörper mit Spezifität für menschliches Tumor-Antigen. Expired - Fee Related DE3751004T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92324486A 1986-10-27 1986-10-27

Publications (2)

Publication Number Publication Date
DE3751004D1 true DE3751004D1 (de) 1995-03-02
DE3751004T2 DE3751004T2 (de) 1995-05-24

Family

ID=25448370

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751004T Expired - Fee Related DE3751004T2 (de) 1986-10-27 1987-10-27 Chimärer Antikörper mit Spezifität für menschliches Tumor-Antigen.

Country Status (17)

Country Link
US (1) US5354847A (de)
EP (1) EP0266663B1 (de)
JP (1) JPH02501886A (de)
AT (1) ATE117370T1 (de)
AU (2) AU626254B2 (de)
DE (1) DE3751004T2 (de)
ES (1) ES2069527T3 (de)
FI (1) FI891984A (de)
GR (1) GR3015810T3 (de)
HU (1) HU209154B (de)
IE (1) IE62304B1 (de)
IL (1) IL84285A (de)
NZ (1) NZ222309A (de)
OA (1) OA09115A (de)
PT (1) PT85995B (de)
WO (1) WO1988003145A1 (de)
ZA (1) ZA878044B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0364096B1 (de) 1988-09-06 2000-03-08 Xoma Corporation Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
DK0460076T3 (da) * 1989-02-24 1996-03-25 Univ California Genetisk manipulerede immunoglobuliner
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
US20050196400A1 (en) * 1991-05-06 2005-09-08 Xoma Technology Ltd. Production of chimeric mouse-human antibodies with specificity to human tumor antigens
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5543499A (en) * 1993-10-29 1996-08-06 Wake Forest University DNA sequence encoding a polypeptide with anti-tumor properties
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DK0966533T3 (da) 1997-02-07 2010-01-04 Us Gov Health & Human Serv Aktivitetsafhængig neurotrof faktor III (ADNF III).
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
EP1438400B1 (de) 2001-10-01 2009-06-17 Dyax Corp. Mehrkettige eukaryontische display-vektoren und deren verwendungen
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CA2489595C (en) * 2002-06-14 2013-05-28 Simon E. Hufton Recombination of nucleic acid library members
WO2005016232A2 (en) 2002-08-01 2005-02-24 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
AU2003901511A0 (en) * 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
US20110064730A1 (en) * 2003-03-28 2011-03-17 Thomas John Gonda Method of modulating angiogenesis
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005059176A1 (en) * 2003-12-15 2005-06-30 Institut Pasteur Repertoire determination of a lymphocyte b population
DE60326052D1 (de) * 2003-12-15 2009-03-19 Pasteur Institut Ermittlung des Repertoires von B-Lymphozyten Populationen
EP2213683B1 (de) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Varianten der Fc Regionen
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
WO2007094754A2 (en) 2005-01-27 2007-08-23 The Regents Of The University Of Califordnia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
AU2006249305B2 (en) 2005-05-26 2012-10-18 Genentech, Inc. Humanized anti-CD40 antibodies and their methods of use
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
US20080213170A1 (en) * 2007-01-23 2008-09-04 Young David S F Cancerous Disease Modifying Antibodies
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US8277651B2 (en) 2009-03-13 2012-10-02 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
KR20140002601A (ko) 2010-07-09 2014-01-08 바이오겐 이데크 헤모필리아 인코포레이티드 키메라 응고 인자
CA2809363A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Hiv core protein specific antibodies and uses thereof
EP3527218A1 (de) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Gerinnungsfördernde verbindungen und verfahren zur verwendung davon
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
AU2013207927B2 (en) 2012-01-10 2017-11-02 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
EP3683314A1 (de) * 2013-10-07 2020-07-22 Prestige Biopharma Pte. Ltd. Bicistronischer expressionsvektor zur antikörperexpression und verfahren zur antikörperherstellung damit
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
PT3383920T (pt) 2015-11-30 2024-04-15 Univ California Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
US10995126B2 (en) 2016-05-04 2021-05-04 National Health Research Institutes Immunogenic peptide containing a b cell epitope of tumor associated antigen L6
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
WO2019018744A1 (en) 2017-07-21 2019-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US20200283537A1 (en) 2017-11-14 2020-09-10 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4486538A (en) * 1978-07-07 1984-12-04 Samuel Bogoch Detection of malignant tumor cells
US4650756A (en) * 1981-08-31 1987-03-17 Sloan Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human renal cancer
US4476538A (en) * 1982-02-01 1984-10-09 Analog Devices, Inc. Trigonometric function generator
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4708862A (en) * 1983-02-22 1987-11-24 Xoma Corporation Radioimmuno detection of human cancers using anti-tumor monoclonal antibody
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4550756A (en) * 1984-01-16 1985-11-05 The Goodyear Tire & Rubber Company Pneumatic tire tread
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US4770993A (en) * 1985-10-31 1988-09-13 Beatrice Companies, Inc. Hybridoma tumor cell lines and their monoclonal antibodies to thaumatin
EP0247091B1 (de) * 1985-11-01 1993-09-29 Xoma Corporation Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies

Also Published As

Publication number Publication date
IL84285A0 (en) 1988-03-31
JPH02501886A (ja) 1990-06-28
AU626254B2 (en) 1992-07-30
GR3015810T3 (en) 1995-07-31
HUT52153A (en) 1990-06-28
FI891984A0 (fi) 1989-04-26
AU8326187A (en) 1988-05-25
AU656633B2 (en) 1995-02-09
IL84285A (en) 1993-03-15
WO1988003145A1 (en) 1988-05-05
ZA878044B (en) 1988-04-25
FI891984A (fi) 1989-04-26
US5354847A (en) 1994-10-11
IE62304B1 (en) 1995-01-25
DE3751004T2 (de) 1995-05-24
EP0266663B1 (de) 1995-01-18
PT85995B (pt) 1990-08-31
HU209154B (en) 1994-03-28
IE872880L (en) 1988-04-27
EP0266663A1 (de) 1988-05-11
NZ222309A (en) 1990-02-26
PT85995A (en) 1987-11-01
ES2069527T3 (es) 1995-05-16
OA09115A (en) 1991-10-31
ATE117370T1 (de) 1995-02-15
AU2810592A (en) 1993-01-28

Similar Documents

Publication Publication Date Title
DE3751004D1 (de) Chimärer Antikörper mit Spezifität für menschliches Tumor-Antigen.
GR3033630T3 (en) Gene expression elements and the production of chimeric mouse-human antibodies.
PT86792A (pt) Monoclonal antibodies against melanoma-associated antigens hybrid cell lines producing these antibodies and use therefor
EP0274394A3 (de) Chimären Antikörper, spezifisch für menschlichen B-Zellen-Oberflächenantigen
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
NO861577L (no) Antigen, antistoff og fremgangsmaate for dets fremstilling og anvendelse derav for diagnostisering.
EP0404003A3 (de) Chimäre Maus-Mensch-KM10-Antikörper, spezifisch für ein menschliches Tumorzellen-Antigen
EP0338395A3 (en) Monoclonal antibodies to pseudomonas aeruginosa, their production and use
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3579808D1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
ATE86261T1 (de) Tumorassoziiertes antigen.
ATE92081T1 (de) Tumorassoziiertes antigen.
DK354288A (da) Kimaert antistof med specificitet over for humant tumorantigen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee